#1 Clinical Trials Search in Europe

Explore popular drugs in clinical trials

Check which drugs are currently being frequently studied.

See also our rare diseases glossary and popular diseases list.

Starting by letter

To open the drugs glossary, select a letter from the list below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All drugs

Most popular drugs

The list below features the most popular substances currently involved in ongoing clinical trials.

Drug Trials
Pembrolizumab 462
Sodium Chloride 431
Carboplatin 345
Cisplatin 287
Paclitaxel 263
Fluorouracil 238
Oxaliplatin 229
Nivolumab 217
Dexamethasone 211
Rituximab 201
Cyclophosphamide 191
Durvalumab 169
Bevacizumab 168
Paracetamol 160
Capecitabine 160
Atezolizumab 147
Docetaxel 133
Prednisone 129
Tocilizumab 126
Prednisolone 125
Gemcitabine 122
Mycophenolate Mofetil 122
Doxorubicin Hydrochloride 118
Venetoclax 118
Pemetrexed 117
Etoposide 116
Infliximab 102
Lenalidomide 102
Semaglutide 96
Acetylsalicylic Acid 94
Ipilimumab 91
Folinic Acid 90
Placebo 89
Paclitaxel Albumin-Bound 85
Daratumumab 83
Calcium Folinate 83
Fludarabine Phosphate 80
Cytarabine 80
Methotrexate 79
Letrozole 77
Dapagliflozin 76
Bortezomib 75
Gemcitabine Hydrochloride 73
Olaparib 72
Obinutuzumab 68
Lenvatinib 67
Azacitidine 67
Tacrolimus 67
Trastuzumab 66
Cetuximab 65
Fulvestrant 64
Irinotecan 63
Irinotecan Hydrochloride Trihydrate 62
Methylprednisolone 59
Temozolomide 59
Cemiplimab 57
Vincristine Sulfate 57
Apixaban 53
Trastuzumab Deruxtecan 53
Lidocaine Hydrochloride Monohydrate 52
Enzalutamide 52
Amoxicillin 51
Betamethasone Sodium Phosphate 50
Dexamethasone Sodium Phosphate 49
Codeine Phosphate 49
Ribociclib 49
Hydrocortisone 48
Exemestane 48
Lidocaine Hydrochloride 48
Buclizine Hydrochloride 47
Empagliflozin 47
Anastrozole 47
Adalimumab 47
Potassium Chloride 46
Clavulanic Acid 45
Tenofovir Alafenamide 44
Pertuzumab 44
Oxygen 44
Pomalidomide 44
Abemaciclib 43
Ibrutinib 43
Clopidogrel 43
Doxorubicin 43
Ruxolitinib 42
Propofol 42
Rivaroxaban 42
Atorvastatin 41
Sulfamethoxazole 41
Cyclophosphamide Monohydrate 41
Trimethoprim 41
Bendamustine Hydrochloride 40
Metformin Hydrochloride 40
Carfilzomib 40
Cabozantinib 40
Emtricitabine 40
Ropivacaine Hydrochloride 40
Palbociclib 40
Linezolid 39
Dostarlimab 38
Acalabrutinib 38

New drugs in trials

The list below features the new substances involved to ongoing clinical trials.

#1 VMX-C001

Clinical trials are studying VMX-C001 in people who take a Factor Xa direct oral anticoagulant and need urgent surgery or another high-bleeding-risk procedure.

3 months ago
#2 LIPASE

Clinical trials are investigating LIPASE, including a new lipase product compared with pancrelipase.

3 months ago
#3 TRIACYLGLYCEROL LIPASE

Clinical trials of TRIACYLGLYCEROL LIPASE are studying a new lipase treatment in adults with exocrine pancreatic insufficiency.

3 months ago
#4 IMA401

Clinical trials are investigating IMA401 in patients with recurrent and/or refractory solid tumors.

3 months ago
#5 ALLERGEN EXTRACTS

Clinical trials are studying BLOMIA TROPICALIS POLYMERIZED EXTRACT as part of a vaccine for dust mite and Blomia tropicalis allergy.

3 months ago
#6 AUR200

Clinical trials are investigating AUR200 in people with generalized myasthenia gravis.

3 months ago

Drugs starting by j

  • 1 

    Jab-21822

    ,

    JAB-21822, also known as glecirasib, is an investigational drug currently being studied in various clinical trials for the treatment of advanced solid tumors, particularly those harboring KRAS G12C mutations. This article provides an overview of the ongoing research on JAB-21822, its potential benefits, and its role in combating different types of cancer.

    Related diseases and areas:

  • 1 

    Jk06

    ,

    A new drug called JK06 is currently being studied in clinical trials for patients with advanced or metastatic cancer that cannot be surgically removed. This article will provide an overview of the ongoing research, explaining the purpose of the study, how it’s conducted, and what researchers hope to learn about JK06’s potential in cancer treatment.

    Related diseases and areas:

  • 1 

    Jk08

    ,

    JK08, a novel recombinant fusion protein, is currently undergoing clinical trials for patients with unresectable locally advanced or metastatic cancer. This groundbreaking study aims to evaluate the safety, effectiveness, and potential of JK08 in treating various types of solid tumors. The trial involves both monotherapy and combination treatments, offering hope for patients with difficult-to-treat cancers.

    Related diseases and areas:

  • 1 

    Jnj-64042056

    ,

    A groundbreaking clinical trial is underway to evaluate the effectiveness of JNJ-64042056, a new drug designed to target phosphorylated tau in individuals with preclinical Alzheimer’s disease. This study aims to assess the drug’s impact on cognitive decline and brain tau burden, offering hope for early intervention in Alzheimer’s disease progression.

    Related diseases and areas:

  • 2 

    JNJ-75276617

    , ,

    A clinical trial is currently investigating JNJ-75276617, a promising new drug for pediatric and young adult patients with relapsed or refractory acute leukemias that have specific genetic alterations (KMT2A, NPM1, or nucleoporin). This Phase I/Ib study aims to determine the optimal dosage of JNJ-75276617 when combined with conventional chemotherapy. The trial focuses on patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and acute leukemia of ambiguous lineage who haven’t responded adequately to previous treatments. By testing different dosages and monitoring safety, researchers hope to find effective treatment options for these challenging cases of leukemia.

    Related diseases and areas:

  • 8 

    Jnj-77242113

    , ,

    JNJ-77242113 is an investigational drug currently being studied in clinical trials for its potential in treating moderate-to-severe plaque psoriasis and ulcerative colitis. This article provides an overview of the ongoing research, focusing on the drug’s efficacy, safety, and potential benefits for patients with these chronic inflammatory conditions.

    Related diseases and areas:

  • 1 

    Jnj-81241459

    ,

    A new clinical trial is underway to assess the effectiveness and safety of JNJ-81241459, a potential breakthrough medication for individuals suffering from moderate to severe plaque psoriasis. This Phase 2b study aims to compare different doses of the drug against a placebo, offering hope for improved treatment options for those affected by this chronic skin condition.

    Related diseases and areas:

  • 1 

    Jtt-861 Monohydrochloride Dihydrate

    ,

    This article discusses a Phase 2a clinical trial investigating the use of JTT-861 Monohydrochloride Dihydrate in patients with heart failure with reduced ejection fraction (HFrEF). The study aims to evaluate the efficacy, safety, and tolerability of JTT-861 when administered for 12 weeks. This multicenter, randomized, double-blind, placebo-controlled trial involves approximately 300 participants and compares two different doses of JTT-861 against a placebo.

    Related diseases and areas:

  • 1 

    Juniper Berry Oil

    ,

    A recent clinical trial is investigating the effectiveness of Juniper Berry Oil, specifically Roleca® juniper 100 mg, in addressing common digestive issues. This study focuses on symptoms such as cramps in the gastrointestinal tract, flatulence, and bloating. The trial aims to evaluate how this natural remedy might improve the quality of life for individuals suffering from persistent dyspeptic digestive complaints.

    Related diseases and areas:

  • 1 

    JX10

    ,

    The ORION study is a significant clinical trial examining JX10, a promising thrombolytic agent for patients with acute ischemic stroke who seek medical care between 4.5 and 24 hours after symptom onset. This multicenter, randomized study aims to determine whether JX10 can improve functional outcomes compared to placebo and assess its safety profile, particularly regarding the risk of brain bleeding. The trial is being conducted in two parts, testing different doses (1mg/kg and 3mg/kg) to identify the optimal treatment approach for patients with late-presenting strokes, potentially expanding treatment options beyond the current narrow time window for stroke intervention.

    Related diseases and areas: